These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7098117)

  • 1. [Change of serum bile acids levels after administration of UDCA and test meals (author's transl)].
    Inaguma H
    Nihon Shokakibyo Gakkai Zasshi; 1982 Feb; 79(2):289. PubMed ID: 7098117
    [No Abstract]   [Full Text] [Related]  

  • 2. [A comparative study of serum bile acid levels (TBA, CG) in liver disease-difference between fasting and UDCA oral loading (author's transl)].
    Hino K; Yamamoto S; Yamashita S; Fukushima K; Ohashi K
    Nihon Shokakibyo Gakkai Zasshi; 1981 Nov; 78(11):2197. PubMed ID: 7328844
    [No Abstract]   [Full Text] [Related]  

  • 3. [Significance and limitations of oral UDCA loading in liver function test].
    Matsuzaki Y; Osuga T; Shoda J; Imawari M; Mitamura K
    Nihon Rinsho; 1984 Jul; 42(7):1671-6. PubMed ID: 6492410
    [No Abstract]   [Full Text] [Related]  

  • 4. [Diagnostic value of oral bile acid tolerance test (author's transl)].
    Matsumoto H; Masamune O; Nunode Y; Ohshiba S
    Nihon Shokakibyo Gakkai Zasshi; 1981 Jul; 78(7):1380-7. PubMed ID: 7311082
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effects of ursodeoxycholic acid on the biliary lipids secretion (author's transl)].
    Yanaura S; Izuka A; Ishikawa S
    Nihon Yakurigaku Zasshi; 1981 Oct; 78(4):261-7. PubMed ID: 7327454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical evaluation of ursodeoxycholic acid. Glucagon tolerance test in patients with chronic liver disease].
    Yamashita Y; Moriyasu F; Kimura T; Ono S; Kawasaki T; Tamada T; Ban N; Nakamura T; Uchino H
    Nihon Shokakibyo Gakkai Zasshi; 1988 Dec; 85(12):2651-7. PubMed ID: 3244182
    [No Abstract]   [Full Text] [Related]  

  • 7. Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis: effect of ursodeoxycholic treatment.
    Chretien Y; Poupon R; Gherardt MF; Chazouilleres O; Labbe D; Myara A; Trivin F
    Gut; 1989 Aug; 30(8):1110-5. PubMed ID: 2767508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The oral ursodeoxycholic acid test and its value in the diagnosis of liver diseases].
    Goszcz A
    Pol Tyg Lek; 1986 Apr; 41(17):547-51. PubMed ID: 3737462
    [No Abstract]   [Full Text] [Related]  

  • 9. Abnormality of oral ursodeoxycholic acid tolerance test in the Dubin-Johnson syndrome.
    Kawasaki H; Yamanishi Y; Kishimoto Y; Hirayama C; Ikawa S; Kuchiba K; Kondo T
    Clin Chim Acta; 1981 Apr; 112(1):13-9. PubMed ID: 7237821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis.
    Matsuzaki Y; Tanaka N; Osuga T; Aikawa T; Shoda J; Doi M; Nakano M
    Am J Gastroenterol; 1990 Jan; 85(1):15-23. PubMed ID: 1967512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of ursodeoxycholic acid on cholesterol gallstone dissolution (author's transl)].
    Nambu M; Kuroda H; Namihisa T; Ohama H; Maeda M
    Nihon Shokakibyo Gakkai Zasshi; 1978 Nov; 75(11):1768-80. PubMed ID: 731984
    [No Abstract]   [Full Text] [Related]  

  • 12. [Medical treatment of gallstones (author's transl)].
    Gérolami A; Montet JC; Marteau C; Reynier MO; Crotte C
    Gastroenterol Clin Biol; 1980; 4(8-9):588-99. PubMed ID: 7000610
    [No Abstract]   [Full Text] [Related]  

  • 13. [A clinical significance of oral ursodeoxycholic acid tolerance test for patients with hepatobiliary diseases by using radioimmunoassay (author's transl)].
    Shinozaki K
    Rinsho Byori; 1981 May; 29(5):475-7. PubMed ID: 7289113
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease.
    Colombo C; Crosignani A; Alicandro G; Zhang W; Biffi A; Motta V; Corti F; Setchell KDR
    J Pediatr; 2016 Oct; 177():59-65.e1. PubMed ID: 27297203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis.
    Colombo C; Setchell KD; Podda M; Crosignani A; Roda A; Curcio L; Ronchi M; Giunta A
    J Pediatr; 1990 Sep; 117(3):482-9. PubMed ID: 2391610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical significance of the determination of serum bile acid and oral bile acid loading test in gastrointestinal diseases].
    Matsuzaki Y; Osuga T; Imawari M; Shoda J; Mitamura K; Kozawa K
    Nihon Shokakibyo Gakkai Zasshi; 1985 May; 82(5):1369-79. PubMed ID: 4032834
    [No Abstract]   [Full Text] [Related]  

  • 17. [The serum lipid changes in the aged subjects by ursodeoxycholic acid administration].
    Nakazawa Y; Fukuo Y; Terashi A
    Nihon Ronen Igakkai Zasshi; 1985 Mar; 22(2):160-6. PubMed ID: 4010042
    [No Abstract]   [Full Text] [Related]  

  • 18. Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration.
    Nakagawa M; Colombo C; Setchell KD
    Hepatology; 1990 Aug; 12(2):322-34. PubMed ID: 2391071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ursodeoxycholic acid and chenodeoxycholic acid on cholesterol and bile acid metabolism.
    Tint GS; Salen G; Shefer S
    Gastroenterology; 1986 Oct; 91(4):1007-18. PubMed ID: 3527851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in serum bile acids during treatment with chenodiol or ursodiol for dissolution of cholesterol gallstones.
    Nowak M; Panveliwalla D; Pertsemlidis D
    Mt Sinai J Med; 1983; 50(3):240-4. PubMed ID: 6604868
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.